Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 2
Tests geranylgeranylacetone to prevent heart rhythm problems after heart surgery
Tests geranylgeranylacetone to prevent atrial fibrillation in adults after heart surgery.
Key facts
- Who runs it
- Stichting Amsterdam UMC
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- EU 2024-514743-28-00
- U1111-1301-9293
- Registry title
- GeranylGeranylAcetone as prevention for postoperative Atrial Fibrillation (GENIALITY)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 146 people, planned
- Started
- 1 Aug 2024
- Planned end
- 1 Aug 2025
- Type of study
- Interventional
- Record updated
- 21 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having heart surgery for a heart valve problem or coronary artery disease. It aims to prevent irregular heartbeat (atrial fibrillation) after surgery.
- Age
- 18 to 80 years in the inclusion criteria; the registry lists 18 to 64 years.
- Sex
- All sexes can join.
- Disease stage
- Planned heart or chest surgery for mitral valve stenosis or regurgitation, and/or aortic valve stenosis or regurgitation, and/or coronary artery disease.
- Earlier treatment
- People who had earlier heart or chest surgery cannot join.
Main reasons for not taking part
- Documented history of atrial fibrillation
- Previous cardiothoracic surgery
- Pre-menopausal women who are nursing, pregnant, or of child-bearing potential
- Chronic malabsorption
- Cancer or history of cancer within 1 year before screening, with two exceptions (treated basal cell carcinoma, in situ cervical carcinoma)
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Aged between 18 and 80 years old
- Elected for cardiothoracic surgery for mitral valve stenosis or regurgitation, and/or aortic valve stenosis or regurgitation, and/or coronary artery disease
Who cannot take part
- Previous cardiothoracic surgery
- Currently enrolled in another drug trial
- Documented history of AF
- Any documented or suspected malignancy or history of malignancy within 1 year prior to screening, except appropriate treated basal cell carcinoma or in situ carcinoma of the cervix
- Not able to undergo the complete study protocol
- Doubt about compliance
- Pre-menopausal women who are nursing, pregnant, or of child-bearing potential
- Chronic malabsorption
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Stichting Amsterdam UMCAmsterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To prevent incidence of postoperative atrial fibrillation on patients undergoing cardiothoracic surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- GeranylGeranylAcetone as prevention for postoperative Atrial Fibrillation (GENIALITY)
- Plain-language title
- Tests geranylgeranylacetone to prevent heart rhythm problems after heart surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-514743-28-00, who can take part
- Record updated
- 21 January 2025